Vor Biopharma (NYSE:VOR) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Vor Biopharma (NYSE:VOR) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $17.50 price objective on the stock.

Other analysts have also issued research reports about the company. Barclays lowered their price target on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Robert W. Baird reduced their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $11.36.

Vor Biopharma Price Performance

Shares of VOR stock traded up $0.12 during trading hours on Friday, hitting $0.96. The stock had a trading volume of 795,417 shares, compared to its average volume of 504,849. Vor Biopharma has a one year low of $0.63 and a one year high of $3.14. The stock’s 50-day moving average price is $0.80 and its two-hundred day moving average price is $1.07. The stock has a market capitalization of $65.53 million, a price-to-earnings ratio of -0.55 and a beta of -0.40.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). As a group, equities research analysts predict that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

Institutional Trading of Vor Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in VOR. Vanguard Group Inc. increased its holdings in shares of Vor Biopharma by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after buying an additional 69,436 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Vor Biopharma during the 1st quarter worth approximately $126,000. Renaissance Technologies LLC boosted its position in shares of Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares during the period. Hsbc Holdings PLC boosted its position in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Vor Biopharma during the 2nd quarter worth approximately $53,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.